Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 7:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 613 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: iron Clear all

Conditions: HIV Dementia
Interventions: Ferumoxytol; Drug
Lead sponsor: University of Hawaii; Other
Eligibility: 19 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Lead Poisoning
Interventions: Ferrous fumarate, Zinc oxide, Placebo; Dietary Supplement
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 6 Years to 8 Years
Enrollment: 602 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2001
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Anemia, Cooley's, Beta-Thalassemia, Hematologic Diseases, Thalassemia, Osteoporosis, Iron Overload, Hypertension, Pulmonary
Interventions: Deferoxamine, Deferiprone, Arginine, Sildenafil, Decitabine; Drug
Lead sponsor: Carelon Research; Other
Eligibility: 1 Year to 75 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 4
States / cities: Oakland, California • Boston, Massachusetts • New York, New York + 1 more

Conditions: Iron-deficiency Anemia (IDA), Pregnancy
Interventions: daily ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill, alternate day ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill; Drug
Lead sponsor: Southern Illinois University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Springfield, Illinois

Conditions: Hookworm Infection, Hookworm Disease
Interventions: Na-GST-1/Alhydrogel®, CpG 10104; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Hematological Diseases
Interventions: Liver Biopsy and MRI T2* MRI; Procedure
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 7 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Anemia
Interventions: Not listed
Lead sponsor: Cornell University; Other
Eligibility: 19 Years to 45 Years · Female only
Enrollment: 350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2023
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Anemia
Interventions: Oral Iron, sodium ferric gluconate; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 8
States / cities: Hot Springs, Arkansas • Orange County, California • Simi Valley, California + 5 more

Conditions: Anemia in Pregnancy, Pre-eclampsia
Interventions: Neevo®, Prenatal vitamins; Other
Lead sponsor: Pamlab, L.L.C.; Industry
Eligibility: 21 Years to 39 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 3
States / cities: Chickasha, Oklahoma • Norman, Oklahoma

Conditions: Infant Development
Interventions: Iron in infant formula; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 1 Day to 4 Months
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Pregnancy
Interventions: Néevo®/ NéevoDHA®; Other
Lead sponsor: Pamlab, Inc.; Industry
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Corpus Christi, Texas

Conditions: Nutritional Deficiency
Interventions: Pearl millet, Biofortified pearl millet; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Months to 36 Months
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Social Determinants of Health (SDOH)
Interventions: Survey using a questionnaire.; Other
Lead sponsor: BayCare Health System; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Iron-deficiency Anemia
Interventions: Cast Iron Pot, Alumnium Pot; Device
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Atherosclerosis
Interventions: Not listed
Lead sponsor: Ohio State University; Other
Eligibility: 40 Years and older · Female only
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Iron Deficiency Anemia
Interventions: Ferrous Sulfate Oral Product; Drug
Lead sponsor: AdventHealth; Other
Eligibility: 29 Weeks to 33 Weeks
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: End Stage Renal Disease
Interventions: Triferic; Drug
Lead sponsor: Rockwell Medical Technologies, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Brain Injury, Central Nervous System Degenerative Disorder, Central Nervous System Infectious Disorder, Central Nervous System Vascular Malformation, Hemorrhagic Cerebrovascular Accident, Ischemic Cerebrovascular Accident, Primary Brain Neoplasm, Brain Cancer, Brain Tumors
Interventions: Ferumoxytol, Tissue Analysis, Magnetic Resonance Imaging; Drug · Other · Procedure
Lead sponsor: Michael Iv; Other
Eligibility: 2 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Iron Deficiency Anaemia
Interventions: iron isomaltoside 1000 (Monofer®), iron sucrose (Venofer®); Drug
Lead sponsor: Pharmacosmos A/S; Industry
Eligibility: 18 Years and older
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Iron Deficiency Anemia, Pregnancy
Interventions: Ferric derisomaltose, Ferrous sulfate; Drug
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 8
States / cities: Birmingham, Alabama • Miami, Florida • Ann Arbor, Michigan + 4 more

Conditions: Healthy, Iron Overload, Liver Fat
Interventions: Non-contrast MRI with novel MRI software; Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 7 Years and older
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Iron Deficiency
Interventions: ionic iron, heme iron polypeptide; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 7 Years to 70 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Malignant Glioma
Interventions: T2 (Observed)-Weighted Imaging, Biospecimen Collection, Magnetic Resonance Imaging; Procedure
Lead sponsor: John M. Buatti; Other
Eligibility: 21 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Episodic Migraine, Chronic Daily Migraine
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

Ferumoxytol-enhanced Brain MRI in HIV-associated Neurocognitive Disorders

Effects of Iron and/or Zinc Supplementation in Mexican School Children Exposed to Lead

Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)

Oral Iron Supplementation on Alternate vs. Consecutive Days for Iron Deficiency Anemia in Pregnancy

Safety and Immunogenicity Study of Na-GST-1 With or Without CpG

Pilot Study of Non-Invasive Assessment of Hepatic And Myocardial Iron Through T2* Magnet Resonance Imaging (MRI) In Patients With Iron Overload

Determinants of Neonatal Anemia in Women Carrying Multiples

Study of the Efficacy and Safety of Ferrlecit in the Maintenance Dosing in Hemodialysis Patients.

A Retrospective Analysis of Neevo® and NeevoDHA® Compared to a Standard Prenatal Vitamin in Anemia During Pregnancy

Early Iron Exposure on the Gut Microbiota in Young Infants

Néevo®/NéevoDHA® P.L.U.S. Program (Progress Through Learning, Understand & Support)

Zinc and Iron Bioavailability From Biofortified Pearl Millet

Effects of Social Determinants of Health on IV Iron Treatments

Use of Cast Iron Pots to Improve Maternal Anemia

Longitudinal Study in Perimenopausal Women With Risk Factors for Atherosclerosis

Donor Breast Milk 2

Pharmacokinetics and Preliminary Bioequivalence of Triferic (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients

Using Ferumoxytol-Enhanced MRI to Measure Inflammation in Patients With Brain Tumors or Other Conditions of the CNS

IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose

Intravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy

Fully Automated High-Throughput Quantitative MRI of the Liver

A Pilot Study Comparing Tolerance of Oral Heme Iron Polypeptide With Oral Ionic Iron

T2 Star Magnetic Resonance Imaging and Biomarker Blood Testing to Predict the Change and Progress of Malignant Gliomas

fMRI of the Brainstem in Migraine Sufferers and Controls. Does Iron Deposition Correlate With Progression of Disease?